GSK Pharmaceuticals reports a temporary production disruption due to a fire at one of its contract manufacturing facilities; ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK) has announced that a fire incident occurred at its contract manufacturing facility, resulting in temporary production disruption of ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Shares in GSK rose by as much as 3 per cent after it struck a deal with Boston Pharmaceuticals to acquire a liver disease drug in a deal that could hit $2 billion. The drug is set to enter late-stage ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...

(Alliance News) - GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to buy steatotic liver disease medication efimosfermin alfa.